Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
2.
Infect Immun ; 68(6): 3667-73, 2000 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-10816526

RESUMEN

Thrombospondin-related anonymous protein (TRAP), a candidate malaria vaccine antigen, is required for Plasmodium sporozoite gliding motility and cell invasion. For the first time, the ability of antibodies against TRAP to inhibit sporozoite infectivity in vivo is evaluated in detail. TRAP contains an A-domain, a well-characterized adhesive motif found in integrins. We modeled here a three-dimensional structure of the TRAP A-domain of Plasmodium yoelii and located regions surrounding the MIDAS (metal ion-dependent adhesion site), the presumed business end of the domain. Mice were immunized with constructs containing these A-domain regions but were not protected from sporozoite challenge. Furthermore, monoclonal and rabbit polyclonal antibodies against the A-domain, the conserved N terminus, and the repeat region of TRAP had no effect on the gliding motility or sporozoite infectivity to mice. TRAP is located in micronemes, secretory organelles of apicomplexan parasites. Accordingly, the antibodies tested here stained cytoplasmic TRAP brightly by immunofluorescence. However, very little TRAP could be detected on the surface of sporozoites. In contrast, a dramatic relocalization of TRAP onto the parasite surface occurred when sporozoites were treated with calcium ionophore. This likely mimics the release of TRAP from micronemes when a sporozoite contacts its target cell in vivo. Contact with hepatoma cells in culture also appeared to induce the release of TRAP onto the surface of sporozoites. If large amounts of TRAP are released in close proximity to its cellular receptor(s), effective competitive inhibition by antibodies may be difficult to achieve.


Asunto(s)
Anticuerpos Antiprotozoarios/farmacología , Vacunas contra la Malaria/uso terapéutico , Malaria/prevención & control , Plasmodium yoelii/inmunología , Proteínas Protozoarias/uso terapéutico , Secuencia de Aminoácidos , Animales , Epítopos , Proteínas de la Membrana/aislamiento & purificación , Modelos Moleculares , Datos de Secuencia Molecular , Pruebas de Neutralización , Fragmentos de Péptidos/inmunología , Estructura Terciaria de Proteína , Proteínas Protozoarias/genética , Proteínas Protozoarias/inmunología , Proteínas Protozoarias/aislamiento & purificación , Vacunación , Virulencia/efectos de los fármacos
3.
J Cell Biol ; 147(5): 937-44, 1999 Nov 29.
Artículo en Inglés | MEDLINE | ID: mdl-10579715

RESUMEN

Most Apicomplexan parasites, including the human pathogens Plasmodium, Toxoplasma, and Cryptosporidium, actively invade host cells and display gliding motility, both actions powered by parasite microfilaments. In Plasmodium sporozoites, thrombospondin-related anonymous protein (TRAP), a member of a group of Apicomplexan transmembrane proteins that have common adhesion domains, is necessary for gliding motility and infection of the vertebrate host. Here, we provide genetic evidence that TRAP is directly involved in a capping process that drives both sporozoite gliding and cell invasion. We also demonstrate that TRAP-related proteins in other Apicomplexa fulfill the same function and that their cytoplasmic tails interact with homologous partners in the respective parasite. Therefore, a mechanism of surface redistribution of TRAP-related proteins driving gliding locomotion and cell invasion is conserved among Apicomplexan parasites.


Asunto(s)
Apicomplexa/fisiología , Apicomplexa/patogenicidad , Infecciones por Protozoos/parasitología , Antígeno 12E7 , Secuencia de Aminoácidos , Sustitución de Aminoácidos/genética , Animales , Antígenos CD/química , Antígenos CD/fisiología , Moléculas de Adhesión Celular/química , Moléculas de Adhesión Celular/genética , Moléculas de Adhesión Celular/fisiología , Citoplasma/genética , Citoplasma/fisiología , Humanos , Datos de Secuencia Molecular , Movimiento , Péptidos/metabolismo , Plasmodium berghei/patogenicidad , Plasmodium berghei/fisiología , Infecciones por Protozoos/metabolismo , Proteínas Protozoarias/química , Proteínas Protozoarias/genética , Proteínas Recombinantes/metabolismo , Alineación de Secuencia , Eliminación de Secuencia , Homología de Secuencia de Aminoácido , Toxoplasma/patogenicidad , Toxoplasma/fisiología
4.
J Am Soc Mass Spectrom ; 10(11): 1131-7, 1999 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-10536819

RESUMEN

A method to aid in the analysis of bacterial samples of unknown concentration by matrix-assisted laser desorption/ionization (MALDI) mass spectrometry is demonstrated. It is shown that in MALDI analysis of bacteria, the intensities of resulting peaks in spectra are sensitive to the microbial concentration. At the high and low ends of the concentration range, no signal can be obtained, leaving very concentrated or very dilute samples indistinguishable. The addition of cytochrome c as an internal control allows the differentiation of these concentrated and dilute samples. The presence of the internal control causes only a 20% to 30% decrease in signal intensity when the bacterial concentration is optimum. However, the signal quality is improved when the internal control is added to some low concentrations of bacteria.


Asunto(s)
Bacterias/química , Proteínas Bacterianas/química , Grupo Citocromo c/química , Escherichia coli/química , Estándares de Referencia , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción , Xanthomonas campestris/química
5.
Rapid Commun Mass Spectrom ; 13(15): 1580-5, 1999.
Artículo en Inglés | MEDLINE | ID: mdl-10421900

RESUMEN

Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOFMS) was used to demonstrate the reproducibility of bacterial spectra collected on different days. The reproducibility of analysis by MALDI-MS of intact Escherichia coli and Bacillus atrophaeus is presented as a replicate culture study in which spectra were collected on ten different occasions over a three-month period and by two different operators. The analysis resulted in the detection of specific biomarkers in the m/z 2000-20 000 range. Some of the peaks in the Escherichia coli spectra are identified by comparison with other published work. All of the spectra obtained are reproducible over the course of the experiment, but operator variability does exist. The Escherichia coli spectra show operator variability while the Bacillus atrophaeus spectra do not. This work demonstrates the utility of MALDI in obtaining consistent spectra from bacteria over a period of time.


Asunto(s)
Bacterias/química , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción/métodos , Bacillus/química , Escherichia coli/química , Reproducibilidad de los Resultados , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción/estadística & datos numéricos , Factores de Tiempo
6.
Cathet Cardiovasc Diagn ; 45(4): 396-9, 1998 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-9863744

RESUMEN

Aspirin therapy is an essential part of the drug regimen for patients with acute myocardial infarction (MI), unstable angina, or after coronary angioplasty and coronary stenting. Recognizing this importance, this study sought to compare the bleeding time in two groups of 10 normal volunteers 4 hr after ingestion of either an enteric-coated aspirin or an uncoated aspirin, assuming that a difference between the two groups could be clinically significant. Defining < or = 8 min as normal, 80% of the uncoated group developed abnormal bleeding times, compared to 10% of the enteric-coated group (P < 0.01). The study demonstrates a significant difference between the two types of aspirin preparations on bleeding times in normal individuals. This strongly suggests that some enteric-coated aspirin preparations may not be as effective as uncoated aspirin in acutely decreasing platelet aggregation. Therefore, uncoated aspirin is recommended in the setting of acute MI, unstable angina, or after percutaneous transluminal coronary angioplasty.


Asunto(s)
Aspirina/farmacología , Agregación Plaquetaria/efectos de los fármacos , Aspirina/administración & dosificación , Tiempo de Sangría , Femenino , Humanos , Masculino , Persona de Mediana Edad , Comprimidos Recubiertos
7.
Antimicrob Agents Chemother ; 42(10): 2731-8, 1998 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-9756786

RESUMEN

Proteasomes degrade most of the proteins inside eukaryotic cells, including transcription factors and regulators of cell cycle progression. Here we show that nanomolar concentrations of lactacystin, a specific irreversible inhibitor of the 20S proteasome, inhibit development of the exoerythrocytic and erythrocytic stages of the malaria parasite. Although lactacystin-treated Plasmodium berghei sporozoites are still invasive, their development into exoerythrocytic forms (EEF) is inhibited in vitro and in vivo. Erythrocytic schizogony of P. falciparum in vitro is also profoundly inhibited when drug treatment of the synchronized parasites is prior, but not subsequent, to the initiation of DNA synthesis, suggesting that the inhibitory effect of lactacystin is cell cycle specific. Lactacystin reduces P. berghei parasitemia in rats, but the therapeutic index is very low. Along with other studies showing that lactacystin inhibits stage-specific transformation in Trypanosoma and Entamoeba spp., these findings highlight the potential of proteasome inhibitors as drugs for the treatment of diseases caused by protozoan parasites.


Asunto(s)
Antimaláricos/farmacología , Cisteína Endopeptidasas/efectos de los fármacos , Inhibidores de Cisteína Proteinasa/farmacología , Complejos Multienzimáticos/efectos de los fármacos , Plasmodium/efectos de los fármacos , Acetilcisteína/análogos & derivados , Acetilcisteína/farmacología , Animales , Eritrocitos/parasitología , Humanos , Hipoxantina/metabolismo , Plasmodium/crecimiento & desarrollo , Complejo de la Endopetidasa Proteasomal , Ratas , Ratas Sprague-Dawley
8.
J Biol Chem ; 272(31): 19205-13, 1997 Aug 01.
Artículo en Inglés | MEDLINE | ID: mdl-9235912

RESUMEN

The malaria circumsporozoite protein (CS), thrombospondin (TSP), and several other proteins including the terminal complement proteins and the neural adhesion molecules F-spondin and Unc-5, share a cell adhesive sequence. In CS this sequence is designated as region II-plus (EWSPCSVTCGNGIQVRIK) and in TSP it is found in the type I repeats. Previous studies aimed at fine mapping the amino acid residues required for cell adhesion have yielded discrepant results. Here we show in three different cell lines that the downstream basic residues are required for cell adhesion whereas the CSVTCG sequence is not. Using mutant Chinese hamster ovary cells selected for deficiencies in proteoglycan synthesis, we show that in wild type cells, heparan sulfate proteoglycans are the binding sites for this motif. This finding is supported by additional experiments with two other cell lines demonstrating that treatment with heparitinase but not chondroitinase abolishes cell adhesion to peptides representing this motif. Using Chinese hamster ovary cell mutants deficient in heparan sulfate proteoglycans but possessing chondroitin sulfate proteoglycans, we show that cell surface chondroitin sulfate proteoglycans can also mediate binding to this motif although higher concentrations of peptides are required for adhesion. Chondroitinase, but not heparitinase, treatment of these cells destroys cell surface-binding sites. Taken together, these results indicate that cell adhesion to this motif involves an interaction between the downstream positively-charged residues and the negatively charged glycosaminoglycan chains of heparan sulfate, or in some cases chondroitin sulfate, proteoglycans on the cell surface.


Asunto(s)
Glicosaminoglicanos/metabolismo , Glicoproteínas de Membrana/química , Proteínas Protozoarias/química , Secuencia de Aminoácidos , Animales , Sitios de Unión , Células CHO , Adhesión Celular , Cricetinae , Glicoproteínas de Membrana/fisiología , Datos de Secuencia Molecular , Proteínas Protozoarias/fisiología , Trombospondinas
9.
Cathet Cardiovasc Diagn ; 26(4): 285-90, 1992 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-1394415

RESUMEN

Specific indications for excimer laser coronary angioplasty (ELCA) are yet undefined. We report two specific applications of ELCA when percutaneous transluminal coronary angioplasty (PTCA) failed: (1) to facilitate balloon crossing a long rigid stenosis that could not be crossed after the lesion was wired, and (2) to overcome prominent elastic recoil of the stenosis after PTCA.


Asunto(s)
Angioplastia Coronaria con Balón , Angioplastia por Láser , Adulto , Anciano , Angiografía Coronaria , Enfermedad Coronaria/cirugía , Enfermedad Coronaria/terapia , Femenino , Humanos , Masculino
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...